Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.4 BRL | -2.83% |
|
-8.75% | -82.80% |
05-10 | CM Hospitalar S/A Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-26 | CM Hospitalar S/A Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.31 for the 2024 fiscal year.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- The company is one of the best yield companies with high dividend expectations.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-82.80% | 140M | - | ||
+25.72% | 75.5B | C+ | ||
-4.79% | 23.38B | C+ | ||
+17.81% | 8.96B | B | ||
-31.67% | 6.83B | B- | ||
+21.98% | 5.59B | B- | ||
+3.85% | 4.26B | B | ||
-3.94% | 4B | B- | ||
+13.98% | 3.49B | C | ||
+10.59% | 3.29B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- VVEO3 Stock
- Ratings CM Hospitalar S/A